Market Updates

The Protein Brewery Raises €30 Million in Series B Funding to Commercialize Fungi Proteins

The company has begun the launch of its Fermotein ingredient in the U.S. and Singapore.

Author Image

By: Mike Montemarano

Associate Editor, Nutraceuticals World

Photo: DMejias | Adobe Stock

The Protein Brewery, a specialist in fungi-based food ingredients, has announced the closing of a €30 million Series B funding round. The funding will help the company commercialize its mycelium based protein and innovation platform to expand production capacity of Fermotein.

The round welcomed new investors, including Invest-NL and the Brabant Development Agency, alongside existing investors such as Novo Holdings, Unovis Asset Management, and Madeli.

Since a Series A funding round four years ago, the company has laid the groundwork to commercialize Fermotein at scale, with greater sales and application expertise, commercialization in the U.S. and Europe, expanding production at the company’s facility in Mijkenbroek, and developing an innovation platform to unlock new nutrition and product applications.

“This funding is a springboard for global expansion,” said Thijs Bosch, CEO of The Protein Brewery. “With Fermotein, we are not just offering another protein, we are redefining how food is made: nutritious, sustainable, and scalable at a lower cost. The Protein Brewery is ready to lead the protein and fiber transition. We are now entering a defining moment: all building blocks of operation are in place and we are ready to accelerate.”

“The Protein Brewery has built the infrastructure, laid the groundwork, and is now positioned to bring biotech-driven food innovation to the global stage. This funding fuels its ability to drive real impact in the food industry,” said Thomas Grotkjær, partner at Novo Holdings.

“With its unique fermentation-based solution, The Protein Brewery stands out in the alternative protein space and strengthens the Netherlands’ leadership in food innovation,” said Daan Meijer, investment manager at Invest-NL. “As a Dutch company driving the protein transition, The Protein Brewery is setting a new standard in sustainability, a vision we are proud to support.”

“We’ve supported The Protein Brewery since its inception, and seeing it scale from an idea into a full-fledged operation is remarkable,” said Daan van Lange, senior investment manager and team lead for climate tech at the Brabant Development Agency.  “The Protein Brewery is a prime example of how local innovation can have a global impact. And it’s happening in Brabant.”

Fermotein Launches in the U.S. and Singapore

Fermotein is a high-protein, high-fiber ingredient that integrates into baked goods, snacks, dairy alternatives, protein shakes, functional bars, and meal replacements, due to its tasteless and odorless nature, and is highly cost-efficient in scaling. The company’s proprietary fungal strain used for the ingredient overcomes key hurdles related to cost-effectiveness that have long hindered other alternative proteins.

Fermotein delivers a unique blend of high-quality protein and essential fibers, and the company is exploring its potential role in satiety and metabolic health, including potential effects on the GLP-1 pathway.

Fermotein is launching in the U.S. with several customers in the coming months, and the company is also expanding its business in Singapore. Market launches in the EU and UK are anticipated to follow once regulatory approvals are completed.

“We see this as a defining moment, not just for The Protein Brewery, but for the next generation of the food ecosystem. The future of protein is about quality, nutrition, and sustainability, and this funding ensures we will play a key role in that future,” said Bosch.

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters